VEDOLIZUMAB (ENTYVIO®) PRESCRIBER ORDER FORM					
Patient Name:	Date of Birth:	Date of Birth:			
Address:	<u>_</u>			_ _	
Phone:	Heigh		hes \square cm	Weight:	\square lbs \square kg
Clinical Information Primary Diagnosis Description: ICD-10 Code:					
Primary Diagnosis Desc	☐ Yes – date of first dose:		ICD-	-10 Code:	
Is this the first dose?	□ No – date of next dose due:	_			
Vedolizumab (Entyvio	o®) refill as directed x 1 year	, resemption			
IV Regimen:	 □ Initial Dose; Infuse 300 mg IV over at least 30 minutes on Weeks 0, 2, and 6. □ Maintenance Dose; Infuse 300mg IV over at least 30 minutes every 8 weeks. □ Other: 				
SubQ Regimen:	☐ Initial dose Weeks 0 and 2; Infuse 300 mg IV over at least 30 minutes. ☐ Initial dose Week 6; Infuse 300mg IV over at least 30 minutes. ☐ Maintenance dose; Inject Prefilled Pen of 108 mg SubQ every 2 weeks. ☐ Other:				
For IV doses, quantity sufficient of Entyvio® 300mg vials will be dispensed to the patient to complete the prescribed treatment plan. In addition, after each infusion the IV tubing will be flushed with NS 30ml using a 50ml bag. For SubQ doses, quantity sufficient of Entyvio® 108mg Prefilled Pens will be dispensed to fulfill prescribed treatment plan. Ancillary Orders					
Anaphylaxis Kit	Allullar	Orders			
If this is a 1 st infusion	n dose, would you like Option Care Health to provi	de an anaphylaxis kit v	with the 1 st dos	se?	
☐ Yes	□ No				
Dosage: • Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SUBQ or IM x 1; repeat x 1 in 5 to 15 min PRN.					min PRN.
 Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg – 25mg max dose) IV or IM; repeat x 1 in 15 min PRN no implementations. 					no improvement.
 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. 					
Medication Orders					
 Acetaminophen 650 mg PO 30 min before infusion, may repeat every 3 to 4 hours as needed for fever or mild discomfort. Patient may decline. Diphenhydramine 25 mg PO 30 min before infusion, may repeat every 4 to 6 hours as needed for mild to moderate allergic reactions. 					
Patient may decline.					orgie reactions.
☐ Methylpre	dnisolone Sodium Succinate 40 mg IV push 20 minutes prior to infusion.				
☐ Other: IV Flush Orders					
☐ Peripheral:	0.9% Sodium Chloride 2 to 3 mL pre-/pc	ost-use.			
☐ <u>Implanted</u>	Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.				
Lab Orders	For maintenance, neparin (100 unit/inc	3 to 3 file every 24 file	ii accessed oi	weekly to monthly if	not accessed.
-	lered at this time.				
Other:					
	nister doses intravenously in the home or alternate				
• ,	nat the use of the indicated treatment is medically	necessary, and I will be	e supervising ti	ne patient s treatmer	it.
Prescriber Signature: Date:					
Prescriber Name:		nformation one:	Fax	··	
Address:		i:	rax	٠.	
		i. fice Contact:			
Fay completed form, insurance information, and clinical documentation to:					

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.